To evaluate the contribution of RAD51, XRCC3, and XRCC2 mutations to breast cancer predisposition, we screened 182 familial Finnish breast or ovarian cancer patients for germline variation in the RAD51 and XRCC3 genes and 342 patients for the XRCC2 gene. The gene discussed is XRCC3; the disease is ovarian carcinoma.